(Q34618544)

3 August 2017

title

Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers (English)

1 reference

3 August 2017

0 references

1 reference

1 reference

A Lindauer

1

1 reference

3 August 2017

P Di Gion

2

1 reference

3 August 2017

F Kanefendt

3

1 reference

3 August 2017

D Tomalik-Scharte

4

1 reference

3 August 2017

M Kinzig

5

1 reference

3 August 2017

M Rodamer

6

1 reference

3 August 2017

F Dodos

7

1 reference

3 August 2017

F Sörgel

8

1 reference

3 August 2017

U Fuhr

9

1 reference

3 August 2017

U Jaehde

10

1 reference

3 August 2017

language of work or name

English

0 references

publication date

7 April 2010

1 reference

Clinical Pharmacology & Therapeutics

3 August 2017

published in

1 reference

3 August 2017

volume

87

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

601-608

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

3 August 2017

1 reference

7 January 2021

Biomarkers of response and resistance to antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Predicting benefit from anti-angiogenic agents in malignancy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Home blood-pressure monitoring in patients receiving sunitinib

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Hypertension as a predictive factor of Sunitinib activity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Bibliography of the current world literature in hypertension

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Molecular mediators of tumor angiogenesis: Enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Molecular basis for sunitinib efficacy and future clinical development

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Management of hypertension in angiogenesis inhibitor-treated patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Pharmacodynamic modeling of time-dependent transduction systems

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Comparison of four basic models of indirect pharmacodynamic responses

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.20

7 January 2021

Identifiers

DOI

10.1038/CLPT.2010.20

1 reference

3 August 2017

1 reference